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THE FINANCIAL IMPACTS OF PHARMACIST INTERVENTION IN INPATIENT
DEPARTMENT OF A LOCAL HOSPITAL IN TAIWAN
Hsiao CL, Lin YM, Chang YT, Chen CC, Tsai CS, Liu HP
Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan, Taiwan
OBJECTIVES: The aims of this study are to evaluate significance of pharmacist
interventions, probability value of adverse drug events (ADE) if no pharmacist rec-
ommendations, and to analyze economic impact of pharmacist recommendations.
METHODS:Data of this retrospective studywere collected betweenDecember 2010
and May 2011. The pharmacist recommendations documented in the electronic
system were included in this study, while the recommendations which were in-
complete, were duplications, or did not require the pharmacist to use clinical judg-
ment were excluded. Data analysis included probability value of ADE if no phar-
macist recommendations (0 to 1.0, 0 defined as completely unlikely, 0.5 as neither
likely nor unlikely, 1.0 defined as very likely), severity of potential ADE (potentially
lethal, serious, significant, minor, or no error), and significance of the intervention
(extremely significant, very significant, significant, somewhat significant, nonsig-
nificant, adverse significance) were determined by two evaluators (one physician
and one is senior pharmacist). The cost analysis mainly looked at cost avoidance.
RESULTS: Seven hundreds and seventy-six pharmacist interventions were docu-
mented in the electronic system fromDecember 2010 to May 2011. 285 recommen-
dationswereexcludedsince therewasnospecific intervention, the recommendations
were not accepted or categorized as duplication. Finally, 491 interventions were in-
cluded in this study. The average probability value of ADE was 0.41. The assumption
that cost of prolonged length of hospital stay due to ADE is about NT 5,000. Therefore, cost
avoidance was NT 1,006,550 in this study. On the other hand, most pharmacist inter-
ventions as percentage of 65.4% were classified as “very significant” by the two
evaluators. CONCLUSIONS: The study illustrated that the pharmacists’ interven-
tions were able to prevent potential adverse drug events and to decrease medical
expenditure thereafter. In conclusion, patient-centered pharmaceutical interven-
tion should be provided continuously to improve quality of medical care.
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OBJECTIVES: In Korea, prescribing evaluation program is being conducted for some
drugs having a high risk of misuse or abuse like antibiotics, injections and expen-
sive drugs. The goal of this policy is to guarantee the adequacy of drug prescription
based onmedical, pharmaceutical, and cost-effective assessment. This could iden-
tify the overall trends of drug prescription for each medical institute as well as
comparison among medical institutes. METHODS: It was conducted using pre-
scribing evaluation index developed byHIRA (Health Insurance ReviewandAssess-
ment Service) using national health insurance claims data. The indexes account for
prescribing patterns such as antibiotics prescription rate, injections prescription
rate, drug cost per prescription day, the number of drugs per prescription, adreno-
cortical hormone prescription rate, duplicated prescription rate of NSAIDs (Non-
Steroidal Anti-Inflammatory Drugs), and indicators for promoting generic
prescription. RESULTS: According to the results of fourth quarter of 2010, antibiot-
ics prescription rate, injections prescription rate and the number of drugs per
prescription were higher in primary care clinics than general hospitals. In case of
drug cost per prescription day, costs were lowest in primary care clinics and were
highest in tertiary hospitals. In case of prescription rate of high price drug, rates
also were highest in tertiary hospitals and the degree of reduction was highest in
primary care clinics. CONCLUSIONS: Since this prescribing evaluation program
conducted, antibiotics prescription rate with acute upper respiratory infections
was dropped by 10%p. By making public the results, it also could induce each
medical institute to improve prescribing patterns by themselves. To take a more
effective policy, financial incentives for medical institutes and/or education for
prescriber are needed in addition to feedback of the results.
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OBJECTIVES: The elderly are vulnerable to adverse drug outcomes due to aging,
multiple chronic illnesses and inappropriate use of polypharmacy. The aim of this
research was to evaluate the outcomes of a collaborative service performing phar-
macist-physicianmedication therapymanagement (PP-MTM)model for polyphar-
macy elderly in Taiwan. METHODS: A randomized, controlled intervention study
was designed and implemented in China Medical University Hospital (CMUH), a
2000-bed academic medical center, in Taiwan. We recruited those loyal, polyphar-
macy elderly patients, who regularly visited more than one medical specialty and
possess more than three chronic diseases in the outpatient departments. While
patients in the intervention group received continuous, pharmacist-initiativemed-
ication therapymanagement of PP-MTMmodel for one year, patients in the control
group received usual care and follow-up assessment (UC group). The collaborative
care in PP-MTM group was provided through reviewing medication-related prob-
lems continuously by clinical pharmacist and discussing further with the clinical
physician team. The following outcomes were assessed: 1) economic: medical ex-
penditure in CMUH; 2) clinical: lipid, kidney profiles, depression scores; and 3)
humanistic: Bathal index, scores of instrumental activities of daily living and EQ-5D
scores. The changes of outcomes frombaseline to the end of implantation among two
groups were compared using inferential analyses. RESULTS: Of 1200 potential pa-
tients, 178 elderly patients were involved. Although PP-MTM group had higher
proportion of diabetics than UC group (46% vs. 25%), the other demographics and
outcomes were comparable at baseline. Over one-year implementation, the PP-
MTM group spent $86,480 USD less than UC group. While the changes of clinical
and humanistic outcomes in the PP-MTM group were preferable on the extent,
there were no statistically significant differences among two groups.
CONCLUSIONS: The implementation of the collaborative PP-MTM model in the
outpatient departments was economically beneficial to the polypharmacy loyal
elderly patients.
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THE INCIDENCE OF POTENTIAL DRUG-DRUG INTERACTIONS ORIGINATING
FROM THE SAME PRESCRIBER
Malone DC, Hines LE, Brown S, Warholak TL
University of Arizona, Tucson, AZ, USA
OBJECTIVES: To determine the frequency of co-prescribing interacting medications
from the same prescriber. METHODS: Data for this study came from submitted
pharmacy claims from the Arizona Medicaid program over a 1 year period. A total
of 15 well established drug interactions were used to identify instances where a
beneficiary received both an object (drug that is affected) and precipitant (drug that
causes the interaction) medications with overlapping therapy. The combinations
included: amiodarone/quinolones; carbamazepine/macrolides; digoxin/amiodra-
one; digoxin/azole antifungals; digoxin/macrolides; simvastatin/amiodarone; lo-
vastatin or simvastatin/azole antifungals; tamoxifen/SSRIs; warfarin/amiodarone;
warfarin/azole antifungals; warfarin/fibrates; warfarin/NSAIDs; warfarin/statins;
warfarin/macrolides; warfarin/thyroid preparations. While all these combinations
are not absolutely contraindicated, viable alternatives exist and/or additionalman-
agement is required. Prescribers were identified using Drug Enforcement Admin-
istration or national provider identifier numbers submitted with pharmacy claims.
The analysis examined the extent that both object and precipitant medications
were attributable to the same prescriber. RESULTS: A total of 1,723,924 prescription
recordswereevaluated, representing38,418 individuals. The total numberofpotential
drug-drug interactions (PDDIs) was 25,553, ranging from11 for digoxin/amiodarone to
6183 for warfarin/statins. There were 4215 unique prescribers in the database. A total
of 3,219 individuals were exposed to at least one PDDI, with 62.7% being female. The
mean (SD) age was 51.1 (12.0). The percentage of PDDIs from the same prescriber
ranged from 15% for tamoxifen/SSRIs to 69% for digoxin/amiodarone. Overall, the
same prescriber ordered both the object and precipitant medication for 50% of the
PDDIs. PDDIs involving acute therapies (e.g., anti-infectives)were less likely to involve
the same prescriber. The mean (SD) number of unique PDDIs per prescriber over the
year periodwas 2.49 (2.26).CONCLUSIONS:This study suggests thatmany PDDIs are
due to same prescriber ordering both medications. This is particularly concerning
since many clinically important PDDIs could have been avoided.
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Park SE1, Yim EY1, Lim SH1, Bae SY1, Lee EK1, Kim KH1, You MY2, Lee BI1
1Health Insurance Review & Assessment Service, Seoul, Seoul, South Korea, 2Health Insurance
Review & Assessment Service, Seoul, South Korea
OBJECTIVES: Assessment on the appropriateness for reimbursement of new drugs
by the Health Insurance Review and Assessment services (HIRA) and negotiation
between the National Health Insurance Corporation (NHIC) and pharmaceutical
companies are conducted for determining the price of them after adapting positive
list system in Korea. In this study, we evaluated the relationship between the
results of the negotiation and the characteristics of the drugs as well as reimburse-
ment decisions in order to identify factors affecting the price.METHODS: The price
cut rate between the company suggesting price accepted by the HIRA and the
negotiated price with the NHIC was calculated by the characteristics of drugs
which had completed the negotiation from 2007 to 2011. Mann-Whitney test were
used to identify any significant differences in the rate with regard to the drugs and
regression analysis was carried out to explore which variables are likely to influ-
ence the rate. RESULTS: The negotiation of 145 ingredients of new drugs were
completed for 5 years and 109 of them were successfully reached on the agree-
ment(75.2%). Therewere no differences in negotiation rate by the characteristics of
the drugs. The average price cut rate of negotiated drugs was 19% (n109, range 0
- 77%). The conditionally accepted drugs (n19) with the price recommended by
the HIRA had significantly higher rate than the others(33% vs 16%, p0.0001). In
addition, that of 71 which failed to demonstrate clinically meaningful improve-
mentwas higher than the others, but showed no significance (21% vs. 15%). ‘Rule of
rescue’ or anticancer drugs showed no significant impact on the rate. The annual
net budget cost and acceptance of the HIRA recommending price, however, signif-
icantly affected the rate(p0.05). CONCLUSIONS: This study might be helpful for
identifying the factors that affect the reimbursement price of the new drugs and
enhancing the predictability for the price.
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ASSESSING AGREEMENT BETWEEN PATIENT ACCESS SCHEMES: REVIEW OF
NICE AND SMC GUIDANCE
Timm B, Leonard SA, Haynes S
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: Risk-sharing schemes have become increasingly frequent in health
technology assessment internationally. The degree of alignment between these
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